The ninth TNM staging of non-small-cell lung cancer (NSCLC) was introduced in 2023 to replace the eighth edition that had been in use since 2017. It provides a standardised universal language to discuss management of NSCLC patients. Outcomes across different patient populations can be better evaluated and this process is undertaken by the International Association for the Study of Lung Cancer Lung Cancer Staging Project team to further refine the staging classification past and present.
Changes in descriptors
There is no change to the size-based T-descriptors. Mediastinal nodal N-descriptors followed previous definitions but are now subdivided into N2a and N2b depending on single or multiple nodal stations involvement respectively. M1c M-descriptors that described multiple extra-thoracic metastases were also subclassified into single (M1c1) or multiple (M1c2) organ system involvement.
Changes in staging
Major revisions were made to stage 2 and 3 disease. Previous T1N1M0 disease is downstaged from stage 2B to 2A. T1N2aM0 disease is now downstaged to 2B whilst T1N2bM0 remained as stage 3A. Previous T2N2M0 and T3N2M0 disease were staged 3A and 3B respectively. Under the new classification, T2N2aM0 (unchanged) and T3N2aM0 (downstaged) are now stage 3A whilst T2N2bM0 (upstaged) and T3N2bM0 (unchanged) are now stage 3B.
Conclusion
The ninth edition NSCLC TNM staging is now in place. It is important to be familiar with it to allow effective communication between surgical and medical oncologists to optimise patient care. It is also pertinent to start collecting and maintaining databases using the revised staging to help us further improve treatment in lung cancer patients.
Rami-PortaR. The TNM classification of lung cancer – a historic perspective. J Thorac Dis2024; 16: 8053–8067.
2.
International Union Against Cancer. Clinical stage classification for malignant tumours of the breast. Br J Surg1959; 47: 330–332.
3.
BeahrsOHCarrDTRubinP. AJC manual for staging of cancer. 1st ed. Chicago: American Joint Committee, 1977; pp. 59-61.
4.
MountainCFCarrDTAndersonWA. A system for the clinical staging of lung cancer. Am J Roentgenol Radium Ther Nucl Med1974; 120: 130–138.
5.
GoldstrawPCrowleyJJ. The International Association for the Study of Lung Cancer international staging project on lung cancer. J Thorac Oncol2006; 1: 281–286.
6.
RuschVWAsamuraHWatanabeH, et al.The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol2009; 4: 568–577.
7.
YoshidaYMurayamaTSatoY, et al.Validation of 7th TNM staging system for lung cancer, based on surgical outcomes. Asian Cardiovasc Thorac Ann2013; 21: 693–699.
8.
DetterbeckFCBoffaDJKimAW, et al.The eight edition lung cancer stage classification. Chest2017; 151: 193–203.
9.
AsamuraHYotsukuraMRami-PortaR, et al.Updates on the Version 9 American Joint Committee on Cancer Staging System for lung cancer. Ann Surg Oncol2025; 32: 4569–4571.
10.
Rami-PortaRNishimuraKKGirouxDJ, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer. J Thorac Oncol2024; 19: 1007–1027.
11.
KatoHIchinoseYOhtaM, et al.A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med2004; 350: 1713–1721.
12.
HamadaCTanakaFOhtaM, et al.Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol2005; 23: 4999–5006.
13.
YamanashiKOkumuraNYamamotoY, et al.Adjuvant chemotherapy for elderly patients with non-small-cell lung cancer. Asian CardiovascThoracic Ann2017; 25: 371–377.
14.
StraussGMHerndonJE2ndMaddausMA, et al.Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol2008; 26: 5043–5051.
15.
PepeCHasanBWintonTL, et al.National Cancer Institute of Canada and intergroup study JBR.10. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and intergroup study JBR.10. J Clin Oncol2007; 25: 1553–1561.
16.
DouillardJYRosellRDe LenaM, et al.Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol2006; 7: 719–727.
17.
ChoiJOhJYLeeYS, et al.Clinical efficacy of adjuvant chemotherapy in stage IB (< 4cm) non-small cell lung cancer patients with high-risk factors. Korean J Intern Med2022; 37: 127–136.
18.
WuYLJohnTGroheC, et al.Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol2022; 17: 423–433.
19.
FelipEAltorkiNZhouC, et al.Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol2023; 34: 907–919.
20.
SpicerJDGarassinoMCWakeleeH, et al.Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2024; 404: 1240–1252.
21.
ZhangJGoldKALinHY, et al.Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol2015; 10: 682–690.
22.
Rami-PortaRNishimuraKKGirouxDJ, et al.Members of the IASLC staging and prognostic factors committee and of the advisory boards, and participating institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer. J Thorac Oncol2024; 19: 1007–1027.
23.
ManiwaTShintaniYOkamiJ, et al.Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations. J Thorac Dis2018; 10: 6828–6837.
24.
DetterbeckF. What to do with “surprise” N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol2008; 3: 289–302.
25.
ErdoğuVÇıtakNSezenCB, et al.Survival impact of unexpected N2 in stage IIIB/N2 non-small cell lung cancer patients. Asian Cardiovascular and Thoracic Annals2023; 31: 238–243.
Ugalde FigueroaPAMarquesECilentoVJ, et al.Completeness of resection and long-term survival of patients undergoing resection for pathologic T3 NSCLC: an International Association for the Study of Lung Cancer analysis. J Thorac Oncol2024; 19: 141–152.
28.
SinghADeebALMathey-AndrewsC, et al.Survival of patients with node-negative lung cancer and chest wall invasion. J Thorac Dis2025; 17: 6451–6460.
29.
Van SchilPEAsamuraHNishimuraKK, et al.The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revisions of the T-descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. J Thorac Oncol2024; 19: 749–765.
30.
PatchellRATibbsPAWalshJW, et al.A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med1990; 322: 494–500.
31.
RazDJLanutiMGaissertHC, et al.Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg2011; 92: 1788–1792.
32.
SabariJKYuHAMahadeviaPJ, et al.Overall survival in EGFR-mutant advanced NSCLC treated with first-line osimertinib: a cohort study integrating clinical and biomarker data in the United States. J Thorac Oncol2025; 20: 1268–1278.
33.
PetersSPaz-AresLGReckM, et al.Long-term survival outcomes with first-line nivolumab plus ipilimumab-based treatment in patients with metastatic NSCLC and tumor programmed death-ligand 1 lower than 1%: a pooled analysis. J Thorac Oncol2025; 20: 94–108.
34.
GomezDRTangCZhangJ, et al.Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol2019; 37: 1558–1565.
35.
GeropoulosGEsagianSMSkarentzosK, et al.Video-assisted thoracoscopic versus open sleeve lobectomy for non-small cell lung cancer: a systematic review and meta-analysis from six comparative studies. Asian Cardiovascular and Thoracic Annals2022; 30: 881–893.
36.
AsamuraHChanskyKCrowleyJ. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol2015; 10: 1675–1684.
37.
PenelNBrichetAPrevostB, et al.Pronostic factors of synchronous brain metastases from lung cancer. Lung Cancer2001; 33: 143–154.
38.
ShimadaYSajiHKakihanaM. Survival outcomes for oligometastasis in resected non-small cell lung cancer. Asian Cardiovasc Thorac Ann2015; 23: 937–944.
39.
Penault-LlorcaFSocinskiMA. Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations. Oncologist2025; 30: oyae357.
